2018.Nov.15
Department of Health (DOH) clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in Hong Kong
Date of occurrence of the event: Nov 15, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: Department of Health (DOH) clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in Hong Kong Countermeasures: N/A Any other […]
This article is password protected.
To view the content, please enter your password in the field below